RJA
AXSM icon

Raymond James & Associates’s Axsome Therapeutics AXSM Stock Holding History

Raymond James & Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$782K Buy
8,701
+58
+0.7% +$5.06K ﹤0.01% 2842
2024
Q2 		$696K Sell
8,643
-186
-2% -$13.8K ﹤0.01% 2860
2024
Q1 		$705K Buy
8,829
+3,412
+63% +$286K ﹤0.01% 2839
2023
Q4 		$431K Sell
5,417
-51
-0.9% -$3.41K ﹤0.01% 3043
2023
Q3 		$382K Sell
5,468
-2,603
-32% -$195K ﹤0.01% 3047
2023
Q2 		$580K Buy
8,071
+3,100
+62% +$229K ﹤0.01% 2841
2023
Q1 		$307K Sell
4,971
-1,923
-28% -$126K ﹤0.01% 3230
2022
Q4 		$532K Buy
6,894
+973
+16% +$58.2K ﹤0.01% 2860
2022
Q3 		$264K Buy
5,921
+15
+0.3% +$750 ﹤0.01% 3260
2022
Q2 		$226K Buy
5,906
+277
+5% +$8.76K ﹤0.01% 3420
2022
Q1 		$233K Buy
5,629
+195
+4% +$6.04K ﹤0.01% 3578
2021
Q4 		$205K Buy
+5,434
New +$200K ﹤0.01% 3686
2021
Q3 		– Sell
-7,134
Closed -$481K – 4118
2021
Q2 		$481K Buy
7,134
+3,298
+86% +$198K ﹤0.01% 3098
2021
Q1 		$217K Hold
3,836
– – ﹤0.01% 3557
2020
Q4 		$313K Sell
3,836
-167
-4% -$12.5K ﹤0.01% 3100
2020
Q3 		$285K Hold
4,003
– – ﹤0.01% 2986
2020
Q2 		$329K Sell
4,003
-264
-6% -$20.3K ﹤0.01% 2864
2020
Q1 		$251K Sell
4,267
-3,408
-44% -$278K ﹤0.01% 2883
2019
Q4 		$793K Sell
7,675
-15,696
-67% -$634K ﹤0.01% 2421
2019
Q3 		$473K Sell
23,371
-2,000
-8% -$51.4K ﹤0.01% 2689
2019
Q2 		$653K Buy
+25,371
New +$509K ﹤0.01% 2485

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's AXSM Position: Q3 2024 in Review

Raymond James & Associates increased its Axsome Therapeutics (AXSM) stake by 0.67% in Q3 2024, buying an estimated $5.06K and bringing the position to 8,701 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #2842.

Raymond James & Associates first reported a position in AXSM in Q2 2019 and has held it in 21 quarters since. The position peaked at $793K in Q4 2019. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Raymond James & Associates held 8,701 shares of Axsome Therapeutics worth $782K as of Q3 2024.
  • Raymond James & Associates bought 58 Axsome Therapeutics shares in Q3 2024, an estimated $5.06K.
  • Axsome Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2842 holding.
  • Raymond James & Associates first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Raymond James & Associates's Axsome Therapeutics position peaked at $793K in Q4 2019.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.